The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases
Open accessAbstract
BACKGROUND: It is unknown whether the reduction in HIV-1 reservoirs seen after allogeneic hematopoietic stem cell transplantation (HSCT) with susceptible donor cells is sufficient to achieve sustained HIV-1 remission. OBJECTIVE: To characterize HIV-1 reservoirs in blood and tissues and perform analytic antiretroviral treatment interruptions to determine the potential for allogeneic HSCT to lead to sustained, antiretroviral-free HIV-1 remission. DESIGN: Case report with characterization of HIV-1 reservoirs and immunity before and after antiretroviral interruption. SETTING: Tertiary care center. PATIENTS: Two men with HIV with undetectable HIV-1 after allogeneic HSCT for hematologic tumors. MEASUREMENTS: Quantification of HIV-1 in various tissues after HSCT and the duration of antiretroviral-free HIV-1 remission after treatment interruption. RESULTS: No HIV-1 was detected from peripheral blood or rectal mucosa before analytic treatment interruption. Plasma HIV-1 RNA and cell-associated HIV-1 DNA remained undetectable until 12 and 32 weeks after antiretroviral cessation. Both patients experienced rebound viremia within 2 weeks of the most recent negative viral load measurement and developed symptoms consistent with the acute retroviral syndrome. One patient developed new efavirenz resistance after reinitiation of antiretroviral therapy. Reinitiation of active therapy led to viral decay and resolution of symptoms in both patients. LIMITATION: The study involved only 2 patients. CONCLUSION: Allogeneic HSCT may lead to loss of detectable HIV-1 from blood and gut tissue and variable periods of antiretroviral-free HIV-1 remission, but viral rebound can occur despite a minimum 3-log10 reduction in reservoir size. Long-lived tissue reservoirs may have contributed to viral persistence. The definition of the nature and half-life of such reservoirs is essential to achieve durable antiretroviral-free HIV-1 remission. PRIMARY FUNDING SOURCE: Foundation for AIDS Research and National Institute of Allergy and Infectious Diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CD4+ Count–Guided Interruption of Antiretroviral Treatment
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,231
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
Chun, T.-W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., et al. (1997) · Nature · doi:10.1038/387183a0 · Cited by 2,050
Keele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,912
Self-citationLong-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802905 · Cited by 1,837
Sáez-Cirión, A., Bacchus, C., Hocqueloux, L., Avettand-Fenoel, V., Girault, I., Lecuroux, C., Potard, V., Versmisse, P., Melard, A., Prazuck, T., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003211 · Cited by 1,011
The Challenge of Finding a Cure for HIV Infection
Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D., & Pomerantz, R. J. (2009) · Science · doi:10.1126/science.1165706 · Cited by 846
Daar, E. S., Moudgil, T., Meyer, R. D., & Ho, D. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104043241405 · Cited by 838
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation
Allers, K., Hütter, G., Hofmann, J., Loddenkemper, C., Rieger, K., Thiel, E., & Schneider, T. (2011) · Blood · doi:10.1182/blood-2010-09-309591 · Cited by 681
Palmer, S., Wiegand, A. P., Maldarelli, F., Bazmi, H., Mican, J. M., Polis, M., Dewar, R. L., Planta, A., Liu, S., Metcalf, J. A., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.10.4531-4536.2003 · Cited by 604
Dinoso, J. B., Kim, S. Y., Wiegand, A. M., Palmer, S. E., Gange, S. J., Cranmer, L., O'Shea, A., Callender, M., Spivak, A., Brennan, T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903107106 · Cited by 441
Cited by
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation
Gupta, R. K., Abdul-Jawad, S., McCoy, L. E., Mok, H. P., Peppa, D., Salgado, M., Martinez-Picado, J., Nijhuis, M., Wensing, A. M. J., Lee, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1027-4 · Cited by 595
International AIDS Society global scientific strategy: towards an HIV cure 2016
International AIDS Society Towards a Cure Working Group, Deeks, S. G., Lewin, S. R., Ross, A. L., Ananworanich, J., Benkirane, M., Cannon, P., Chomont, N., Douek, D., Lifson, J. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4108 · Cited by 425
Self-citationTargeting the Latent Reservoir for HIV-1
Sengupta, S., & Siliciano, R. F. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.030 · Cited by 340
Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys
Borducchi, E. N., Liu, J., Nkolola, J. P., Cadena, A. M., Yu, W.-H., Fischinger, S., Broge, T., Abbink, P., Mercado, N. B., Chandrashekar, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0600-6 · Cited by 306
Ghosn, J., Taiwo, B., Seedat, S., Autran, B., & Katlama, C. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31311-4 · Cited by 306
Li, J. Z., Etemad, B., Ahmed, H., Aga, E., Bosch, R. J., Mellors, J. W., Kuritzkes, D. R., Lederman, M. M., Para, M., & Gandhi, R. T. (2015) · AIDS · doi:10.1097/qad.0000000000000953 · Cited by 287
Self-citationAd26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys
Borducchi, E. N., Cabral, C., Stephenson, K. E., Liu, J., Abbink, P., Ng’ang’a, D., Nkolola, J. P., Brinkman, A. L., Peter, L., Lee, B. C., et al. (2016) · Nature · doi:10.1038/nature20583 · Cited by 276
Self-citationEradicating HIV-1 infection: seeking to clear a persistent pathogen
Archin, N. M., Sung, J. M., Garrido, C., Soriano-Sarabia, N., & Margolis, D. M. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3352 · Cited by 275
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1
Hill, A. L., Rosenbloom, D. I. S., Fu, F., Nowak, M. A., & Siliciano, R. F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406663111 · Cited by 265
Self-citationJensen, B.-E. O., Knops, E., Cords, L., Lübke, N., Salgado, M., Busman-Sahay, K., Estes, J. D., Huyveneers, L. E. P., Perdomo-Celis, F., Wittner, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02213-x · Cited by 158
Rust, B. J., Kean, L. S., Colonna, L., Brandenstein, K. E., Poole, N. H., Obenza, W., Enstrom, M. R., Maldini, C. R., Ellis, G. I., Fennessey, C. M., et al. (2020) · Blood · doi:10.1182/blood.2020006372 · Cited by 58
RetractedSáez-Cirión, A., Mamez, A.-C., Avettand-Fenoel, V., Nabergoj, M., Passaes, C., Thoueille, P., Decosterd, L., Hentzien, M., Perdomo-Celis, F., Salgado, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03277-z · Cited by 57
Development of Lentiviral Vectors for HIV-1 Gene Therapy with Vif-Resistant APOBEC3G
Delviks-Frankenberry, K. A., Ackerman, D., Timberlake, N. D., Hamscher, M., Nikolaitchik, O. A., Hu, W.-S., Torbett, B. E., & Pathak, V. K. (2019) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2019.10.024 · Cited by 21
Claiborne, D. T., Detwiler, Z., Docken, S. S., Borland, T. D., Cromer, D., Simkhovich, A., Ophinni, Y., Okawa, K., Bateson, T., Chen, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55873-3 · Cited by 16
“Furthermore, the failure of allogeneic HSCT with CCR5 WT/ Δ 32 heterozygous HSPCs to prevent post-transplant HIV rebound 11 suggests that the minimum frequency of disrupted CCR5 disruption necessary to achieve a cure is high.”
Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantation
Gaebler, C., Kor, S., Allers, K., Perotti, M., Mwangi, D., Meixenberger, K., Hanke, K., Trenkner, T., Kraus, T., Sha, Y., et al. (2026) · Nature · doi:10.1038/s41586-025-09893-0 · Cited by 16
Su, H., Mueller, A., & Goldstein, H. (2024) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000858 · Cited by 13
Target product profile for cell-based and gene-based therapies to achieve a cure for HIV
Lewin, S. R., Bansbach, C., Kemps, D., Mathae, L., Das, K. T., McCune, J. M., Deeks, S. G., & Ndung'u, T. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(24)00277-7 · Cited by 9
Metadata
- Authors
- Henrich, T. J., Hanhauser, E., Marty, F. M., Sirignano, M. N., Keating, S., Lee, T.-H., Robles, Y. P., Davis, B. T., Li, J. Z., Heisey, A., Hill, A. L., Busch, M. P., Armand, P., Soiffer, R. J., Altfeld, M., & Kuritzkes, D. R.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2014-09-02
- Volume
- 161
- Issue
- 5
- Pages
- 319-327
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2047300635
- Cited by
- 401
- References
- 31
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.